Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Enact Holdings Inc (ACT) vs ARK Genomic Revolution ETF (ARKG) Price & Performance

Enact Holdings IncTrade
ARK Genomic Revolution ETFTrade

Price performance (Past 24H)

Key statistics

Enact Holdings Inc vs ARK Genomic Revolution ETF — how do they compare? Enact Holdings Inc trades at $49.07 (market cap $6.67B), while ARK Genomic Revolution ETF trades at $44.31. The key difference: Enact Holdings Inc pays a 1.98% dividend while ARK Genomic Revolution ETF pays none. Which is the better fit depends on your goals.

ACTARKG
Market Cap
$6.67B
Sector
TechnologySector/Thematic
52-Week High
$49.12$44.55
52-Week Low
$34.93$24.02
Enterprise Value
$6.96B
Dividend Yield
1.98%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Enact Holdings Inc

ACT trades at $48.96, up 0.6% today, near the consensus price target of $49.00. The stock shows strong fundamentals with a P/E of 10.23 and robust net income margin of 54.51%. Recent Q2 2026 earnings beat expectations at $1.26 per share. Technical indicators signal a bullish trend with moving averages supporting upside momentum. The company maintains consistent dividend payments and positive revenue growth projections.

Outlook remains positive with analyst consensus favoring buy/hold ratings and price targets suggesting limited upside. Key risks include execution challenges and market volatility. Earnings growth and dividend consistency provide support, but investors should monitor competitive pressures and macroeconomic factors that could impact performance.

ARK Genomic Revolution ETF

ARKG, the ARK Genomic Revolution ETF, trades at $43.04, up 6.06% in the past 24 hours, with a bullish technical signal from moving averages and ADX indicators. The ETF focuses on small- and mid-cap biotech stocks, with its top 10 holdings comprising 59% of the portfolio and a long-term EPS growth rate of 10.7%. Recent news highlights its recovery from a 15% correction, with support emerging at key levels.

The outlook for ARKG is positive, driven by biotech sector tailwinds including a friendlier FDA, strong M&A activity, and AI-driven drug discovery. Risks include high concentration in volatile biotech names and sensitivity to broader market sell-offs. Investors should weigh the growth potential against the inherent volatility of genomics investments.

Returns comparison

Trailing returns across standard periods

About Enact Holdings Inc

Enact Holdings is a leading private mortgage insurance provider in the U.S. It partners with lenders to offer credit enhancement and risk management solutions, helping more borrowers achieve and maintain homeownership.

Read more on ACT

About ARK Genomic Revolution ETF

ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.

Read more on ARKG